About this Medicine article
Outcomes of hormone-responsive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC) patients (P) according to their starting first-line (1st) treatment (T): chemotherapy (CT) or hormonal therapy (HT) by Bighin, C.; Poggio, F.; Dozin, B.; Ceppi, M.; Bruzzi, P.; D'Alonzo, A.; Giraudi, S.; Levaggi, A.; Lambertini, M.; Miglietta, L.; Vaglica, M.; Fontana, V.; Iacono, G.; Pronzato, P.; Del Mastro, L. is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Bighin, C.; Poggio, F.; Dozin, B.; Ceppi, M.; Bruzzi, P.; D'Alonzo, A.; Giraudi, S.; Levaggi, A.; Lambertini, M.; Miglietta, L.; Vaglica, M.; Fontana, V.; Iacono, G.; Pronzato, P.; Del Mastro, L.
- Publisher
- Oxford University Press; Elsevier BV (ISSN 0923-7534)
- Published
- 2015
- Field
- Medicine (Health Sciences)